BioPharmSignal logoBioPharmSignal

Biotech News

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Xenon (XENE)XenonCompany update

VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced

Related news

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

XENEXenon2026-10-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CGTXCognition Therapeutics2026-09-08 11:30 EST

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

VYGRVoyager Therapeutics2026-09-01 12:00 EST

Voyager to Present at Upcoming Investor Conferences

MNOVMediciNova2026-10-06 10:00 EST

MediciNova to Participate in the Maxim Growth Summit

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

AXSMAxsome2026-08-31 11:00 EST

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

TEVATeva Pharmaceutical Industries2026-08-28 10:17 EST

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

View all latest news

Xenon

Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....

Recent company news

XENEXenon2026-10-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-09-21 20:01 EST

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

XENEXenon2026-08-28 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
36.57 USD
Market cap
5.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States